Literature DB >> 10614926

Ocular muscle and eyelid surgery in thyroid-associated orbitopathy.

J Esser1, A Eckstein.   

Abstract

The aim of ocular muscle surgery in Graves' disease is to determine how an optimal normalization of ocular motility disorders - diplopia, compensatory head posture, eyelid dispositions - can be achieved. The results of ocular muscle surgery of fibrotic ocular muscles allow the following conclusions to be drawn. Correcting the motility disorder can be precisely dosed by recessing only one fibrotic ocular muscle with a strabismic angle of up to 15 degrees. This leads to reproducible and dependable results, with a dose-effect coefficient independent of the initial strabismus angle. Indications as to the amount of surgery and which side should be varied according to horizontal an vertical deviations, and are also dependent on the compensatory head posture. Improvement of the binocular visual field is possible in nearly all cases. Over corrections occur more often when the muscle is not directly fixed at the sclera but adjusted on the following day. The time factor is important both before and after the operation. Before the operation, the motility status should have been stable for at least six months. Postoperatively, within the first few days, an insufficient correction should be expected, however this should not lead to premature revision of the amount of surgery. The surgery of the vertical rectus muscles influences the eyelid position. The upper lid retraction is improved with surgery on the vertical extraocular muscle and depends on prior upper lid motility. In contrast, an increase in lower lid retraction is not dependent on an inferior rectus recession. The results permit a precise series of steps to be drawn up in Graves' disease regarding surgical indications, proportionally correcting each side, and the dosage of ocular muscle operations.

Entities:  

Mesh:

Year:  1999        PMID: 10614926     DOI: 10.1055/s-0029-1212189

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  8 in total

Review 1.  [Endocrine orbit disorders. Pathogenesis, clinical presentation and examination, stage-dependent therapy].

Authors:  A Eckstein; J Esser
Journal:  Ophthalmologe       Date:  2003-10       Impact factor: 1.059

2.  [Surgical therapy in Graves' orbitopathy].

Authors:  J Kaminsky; G J Ridder; A Eckstein; M Metzger; F Beisse
Journal:  Ophthalmologe       Date:  2011-05       Impact factor: 1.059

Review 3.  [Graves' ophthalmopathy].

Authors:  A Eckstein; D Dekowski; D Führer-Sakel; U Berchner-Pfannschmidt; J Esser
Journal:  Ophthalmologe       Date:  2016-04       Impact factor: 1.059

4.  [Update on endocrine orbitopathy].

Authors:  A Eckstein; U Berchner-Pfannschmidt; D Führer; J Esser
Journal:  Ophthalmologe       Date:  2013-11       Impact factor: 1.059

5.  Orbital decompression in the system of treatment for complicated thyroid eye disease: case report and literature review.

Authors:  Dilyara S Ismailova; Irina M Belovalova; Yaroslav O Grusha; Natalya Y Sviridenko
Journal:  Int Med Case Rep J       Date:  2018-10-01

6.  Elongation of the inferior rectus tendon with fascia lata graft for large vertical squint angles in patients with Graves' orbitopathy.

Authors:  Julia Prinz; Kathi Hartmann; Filippo Migliorini; Karim Hamesch; Peter Walter; Matthias Fuest; David Kuerten
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-05-19       Impact factor: 3.535

Review 7.  Orbital decompression in thyroid eye disease.

Authors:  N Fichter; R F Guthoff; M P Schittkowski
Journal:  ISRN Ophthalmol       Date:  2012-11-12

8.  Medial Rectus Tendon Elongation with Bovine Pericard (Tutopatch®) in Thyroid-Associated Orbitopathy: A Long-Term Follow-Up including Oculodynamic MRI.

Authors:  Monika Wipf; Britt-Isabelle Berg; Anja Palmowski-Wolfe
Journal:  J Ophthalmol       Date:  2018-07-24       Impact factor: 1.909

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.